Comparator Sourcing from Emerging Market

Little known facts about SourcingComparators from Emerging Markets with Confidence

By

DR. PIYUSH GUPTA (MBBS, MBA)
ASSOCIATE DIRECTOR – BUSINESS DEVELOPMENT
GNH INDIA
MUMBA, INDIA

Index
  1. Facts: Biosimilar Opportunity 2020
  2. Facts: About Biologics
  3. Global Regulatory Pathway
  4. Comparator Examples From Market
  5. Key regulations governing comparator sourcing
  6. Comparator Souring Organisation – Roles and Services.
    1. Facts: Biosimilar Opportunity 2020
      Biosimilar-Opportunity

      • Biologic drugs with sales over $100 billion set to loose patent by 2020
      • Over 3000 companies globally are in the race to develop Biosimilars / Biobetters
      • Over 1300 biosimilars candidates under development
      • The demand for Comparators / RLDs has been estimated at 500,000 units for phase 1 trial through Phase III trials!
    1. Facts: About Biologics
      • If Aspirin’s molecular mass is 180 daltons, that of a Biologic such as mABs is more than 150,000 daltons

      Aspirin’s-molecular-mass

      Facts-About-Biologics

      Facts: About Biologics – complex manufacturing process

      complex-manufacturing-process

      Facts : Biologic Manufacturing
      • Every Biologic product displays a certain degree of variability even between different batches of the same product.
      • Even minor changes in production process have to approved by NHAs
      • For example, Genzyme opened a new large plant in an attempt to produce Myozyme (alglucosidase alfa), but the FDA did not consider the product in the new plant to be the same as Myozyme.
      • Instead, Genzyme had to get approval from the FDA through a BLA (Biologic licensing application) for an entirely new biologic, Lumizyme (alglucosidase alfa), which was produced at the new plant. This resulted in a better biologic with new exclusivity.
Facts: Inherent Variability

reference-biologic

    1. Global Regulatory Pathway
      How does a Biologic travel from SRA to Emerging Market

      Emerging-Market

      Global-Regulatory-Pathway

      Pathway to Emerging Markets: Product registration Module 1 – CPP and FSC

      CTD-Triangle

      What does a CPP look like ?

      What-does-a-CPP-look-like

      Regulatory – Registration
        • Module 1 – General Information:

      One of the most important requirement of module 1 is CPP (Certificate of Pharmaceutical Origin). CPP is a certificate developed under WHO (World Health Organisation) Certification scheme in 1975 and most recently revised in 1997.Detailed information can be read here : http://www.who.int/medicines/areas/ quality_safety/regulation_legislation/certification/guidelines/en/

    1. Comparator Examples From Market
      Sourced from USA

      Sourced-from-USA

      Authorised in USA

      Authorised-in-USA

      Sourced from France

      Sourced-from-France

      Authorised in France

      Authorised-in-France

      Authorised-in-USA-12

      Authorised-in-USA-13

      Taking a product from SRA to Emerging Market

      Emerging-Market

      Is this possible without CPP, eCTD, Registration pathway ?
    2. Key regulations governing comparator sourcing
      Regulatory Senario – USA
      • Important act governing Biologic and Biosimilar Trade:
      • Guidelines on Similar Biological Medicinal product:http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf
      • Section 3.2: Choice of reference product:
      • Restriction: “The reference medicinal product must be a medicinal product authorised in the EEA, on the basis of a complete dossier in accordance with the provisions of Article 8 of Directive 2001/83/EC, as amended”
      • “However, with the aim of facilitating the global development of biosimilars and to avoid unnecessary repetition of clinical trials, it may be possible for an Applicant to compare the biosimilar in certain clinical studies and in in vivo non-clinical studies (where needed) with a non-EEA authorised
  1. Comparator Souring Organisation
    CSO – Comparator Sourcing Organisation
    • Why CSO ?
    • Sourcing of Reference drugs / Comparators has become an “Achilles Heel” of this industry.
    • Ask for 1000 pack – Sorry we offer only 50.
    • Ask for 3 batches – Sorry we have only 1 batch.
    • Ask for CoA – Sorry not provided.
    • Because Sponsors and CROs should be able to focus on trials.
    • CSO such as GNH India a specialised wholesaler of Drugs who understand the complex global regulatory frame work and can help Sponsors and CROs cut cost
    • We navigate the treacherous path of comparator sourcing for you, so you could FOCUS on Development.
    • A 1000 packs – Done
    • 3 Batches – Done
    • CoA, CoC, Pedigree dossier, Temperature record, Recall Agreement –DONE
    • Ship to Timbuktu – Done
    • Cost effective sourcing from Emerging markets can bring this down to 5 – 10%

thank-you
global-leader-local-partner

Other Resources

Comparator Sourcing, Europe 2019

Comparator Sourcing, Europe 2019

view & download

Comparator Sourcing from Row Markets : Busting Myths!

Comparator Sourcing from Row Markets : Busting Myths!

view & download

Our Services

Name Patient Supply

Name Patient Supply

Name Patient Program GNH India has an expert team and world class infrastructure to source the medicines from across the...

read more

Validated Cold Chain Shipment

Validated Cold Chain Shipment

With shifting of pharma industry from synthetic molecules to biologic, proteins etc. temperature maintenance has become as important as the...

read more

Comparator Sourcing for Clinical Trials

Comparator Sourcing for Clinical Trials

GNH India brings over 10 years of experience in Comparator Sourcing services from India and RoW markets. Our Service included...

read more